ECHO

A2O is developing a first in class astrocyte reprogramming therapy that generates new oligodendrocytes to promote remyelination, restore function, and prevent progression in demyelinating diseases.

For patients diagnosed with prion disease, or those that carry a familial mutation that predisposes them to these disorders, Heprion—short for Harnessing evolution for the treatment of prion diseases—is developing a first-in-class intravenously delivered gene therapy that leverages a biological phenomenon refined through evolution to target the root cause of neurodegenerative diseases, including prion diseases.

Neuropeutics is developing first-in-class, disease-modifying small molecules targeting the root causes of neurodegenerative diseases, beginning with ALS, with the potential to halt disease progression, extend survival, and improve quality of life.

Aortico transforms routine aortic imaging into a personalized assessment of aortic dissection risk, giving clinicians a better way to triage growing patient populations. By identifying high-risk patients missed by current assessment, Aortico supports earlier life-saving intervention, more confident clinical decisions, and more efficient use of hospital resources.

ArteraNova’s NanoSmooth is a next-generation vascular healing platform. Their non-cytotoxic, smooth muscle-selective therapeutic peptide, conjugated with a nanoparticle, selectively arrests migrating smooth muscle cells without hindering endothelial recovery. Delivered by an angioplasty balloon, NanoSmooth provides targeted therapy to prevent restenosis while reducing toxicity, thrombosis, repeat interventions, and reliance on blood thinners.